NRx Pharmaceuticals (NASDAQ:NRXP) Receives "Buy" Rating from D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report)'s stock had its "buy" rating reiterated by D. Boral Capital in a report released on Friday,Benzinga reports. They presently have a $31.00 price objective on the stock.

NRXP has been the topic of several other reports. BTIG Research assumed coverage on NRx Pharmaceuticals in a research report on Wednesday, April 2nd. They set a "buy" rating and a $18.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and set a $19.00 price objective on shares of NRx Pharmaceuticals in a research report on Thursday, March 20th. Wall Street Zen upgraded NRx Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, Ascendiant Capital Markets increased their price objective on NRx Pharmaceuticals from $45.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, NRx Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $28.50.

NRx Pharmaceuticals Price Performance

NASDAQ NRXP traded up $0.40 during trading on Friday, reaching $3.67. The company's stock had a trading volume of 769,020 shares, compared to its average volume of 407,489. The stock has a market capitalization of $63.45 million, a PE ratio of -1.71 and a beta of 1.54. The firm has a fifty day moving average of $2.21 and a 200 day moving average of $2.33. NRx Pharmaceuticals has a one year low of $1.10 and a one year high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.06. The firm had revenue of $1.14 million for the quarter, compared to the consensus estimate of $1.14 million. Research analysts expect that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NRx Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Sassicaia Capital Advisers LLC bought a new position in NRx Pharmaceuticals during the 4th quarter worth approximately $33,000. Squarepoint Ops LLC bought a new position in shares of NRx Pharmaceuticals during the fourth quarter valued at about $56,000. Millennium Management LLC bought a new position in shares of NRx Pharmaceuticals during the fourth quarter valued at about $61,000. Anson Funds Management LP raised its stake in shares of NRx Pharmaceuticals by 30.3% during the fourth quarter. Anson Funds Management LP now owns 185,660 shares of the company's stock valued at $408,000 after acquiring an additional 43,135 shares during the last quarter. Finally, AdvisorShares Investments LLC raised its position in NRx Pharmaceuticals by 138.5% during the 4th quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company's stock valued at $683,000 after purchasing an additional 180,229 shares during the last quarter. 4.27% of the stock is currently owned by institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.